SJH 14-095-Alliance A081105- A randomized double blind placebo controlled study of Erlotinib or placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) (Alchemist 2)

This randomized phase III trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase III
All Other|Cancer
Timothy Byun, M.D.
Lavinia Dobrea
  • St. Joseph Hospital of Orange
  • xSJH Southern California